|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
638,922 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$60,375,372 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
11 |
15 |
24 |
57 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-01-02 |
4 |
OE |
$12.99 |
$64,950 |
I/I |
5,000 |
55,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-12-24 |
4 |
AS |
$68.71 |
$687,143 |
I/I |
(10,000) |
50,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-12-24 |
4 |
A |
$12.99 |
$129,900 |
I/I |
10,000 |
60,740 |
|
- |
|
Grey Michael G |
Director |
|
2013-12-11 |
4 |
S |
$69.66 |
$2,089,680 |
D/D |
(30,000) |
23,050 |
|
- |
|
Grey Michael G |
Director |
|
2013-12-11 |
4 |
OE |
$17.33 |
$651,300 |
D/D |
30,000 |
53,050 |
|
- |
|
Lewis Alan |
Director |
|
2013-12-09 |
4 |
S |
$69.91 |
$1,572,982 |
D/D |
(22,500) |
19,300 |
|
- |
|
Lewis Alan |
Director |
|
2013-12-09 |
4 |
OE |
$26.49 |
$686,775 |
D/D |
22,500 |
41,800 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-12-09 |
4 |
S |
$69.55 |
$906,010 |
D/D |
(13,026) |
14,880 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-12-09 |
4 |
OE |
$14.39 |
$253,183 |
D/D |
13,026 |
27,906 |
|
- |
|
Lawlis V Bryan |
Director |
|
2013-12-09 |
4 |
S |
$69.76 |
$202,301 |
D/D |
(2,900) |
11,400 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-12-05 |
4 |
AS |
$69.70 |
$348,485 |
I/I |
(5,000) |
50,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-12-05 |
4 |
A |
$12.99 |
$64,950 |
I/I |
5,000 |
55,740 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-12-02 |
4 |
AS |
$70.14 |
$631,273 |
D/D |
(9,000) |
37,950 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-12-02 |
4 |
OE |
$39.06 |
$351,540 |
D/D |
9,000 |
46,950 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-11-20 |
4 |
A |
$65.89 |
$527 |
D/D |
8 |
68,760 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-11-14 |
4 |
OE |
$12.99 |
$64,950 |
I/I |
5,000 |
50,740 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-11-13 |
5 |
GA |
$0.00 |
$0 |
I/I |
92 |
11,047 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-11-13 |
5 |
GD |
$0.00 |
$0 |
D/D |
92 |
60,350 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-11-05 |
4 |
AS |
$62.36 |
$311,779 |
I/I |
(5,000) |
45,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-11-05 |
4 |
OE |
$12.99 |
$64,950 |
I/I |
5,000 |
50,740 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-11-01 |
4 |
AS |
$63.16 |
$6,253 |
D/D |
(99) |
14,880 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-10-31 |
5 |
A |
$27.91 |
$2,567 |
D/D |
92 |
60,422 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-10-31 |
5 |
A |
$55.44 |
$4,047 |
D/D |
73 |
38,023 |
|
- |
|
Davis George Eric |
SVP, Chief Commercial Of |
|
2013-10-31 |
5 |
A |
$27.91 |
$1,339 |
D/D |
48 |
50,156 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-10-31 |
5 |
A |
$27.91 |
$7,758 |
D/D |
278 |
8,725 |
|
- |
|
1298 Records found
|
|
Page 6 of 52 |
|
|